Key Points
- Cadrenal Therapeutics CEO Quang Pham sold 6,476 shares on May 11 at an average price of $5.76, totaling about $37,302. The transaction was made under a pre-arranged Rule 10b5-1 trading plan.
- After the sale, Pham still directly owned 188,448 shares valued at roughly $1.09 million, representing a 3.32% reduction in his stake.
- The company recently reported a smaller-than-expected quarterly loss of ($1.04) EPS versus the estimated ($1.51), while analysts currently rate the stock Hold on average with a $13.00 price target.
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) CEO Quang Pham sold 2,989 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $4.93, for a total value of $14,735.77. Following the completion of the transaction, the chief executive officer directly owned 182,161 shares in the company, valued at $898,053.73. The trade was a 1.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Cadrenal Therapeutics Price Performance
Shares of Cadrenal Therapeutics stock opened at $4.96 on Friday. Cadrenal Therapeutics, Inc. has a 1 year low of $4.21 and a 1 year high of $15.99. The business has a 50-day moving average of $5.31 and a two-hundred day moving average of $7.18. The company has a market capitalization of $14.24 million, a P/E ratio of -0.88 and a beta of 1.81.
Cadrenal Therapeutics (NASDAQ:CVKD - Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.51) by $0.47. On average, equities analysts anticipate that Cadrenal Therapeutics, Inc. will post -5.52 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on the company. Weiss Ratings restated a "sell (e+)" rating on shares of Cadrenal Therapeutics in a report on Monday, April 20th. HC Wainwright decreased their price objective on Cadrenal Therapeutics from $32.00 to $13.00 and set a "buy" rating for the company in a report on Tuesday, April 7th. Finally, Wall Street Zen upgraded Cadrenal Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday, May 9th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $13.00.
Get Our Latest Stock Analysis on CVKD
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the company. Citadel Advisors LLC bought a new position in shares of Cadrenal Therapeutics during the third quarter worth about $274,000. DRW Securities LLC bought a new position in shares of Cadrenal Therapeutics during the fourth quarter worth about $171,000. JPMorgan Chase & Co. bought a new position in shares of Cadrenal Therapeutics during the third quarter worth about $103,000. Finally, Geode Capital Management LLC grew its holdings in shares of Cadrenal Therapeutics by 14.3% during the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company's stock worth $98,000 after buying an additional 1,818 shares in the last quarter. 7.92% of the stock is currently owned by institutional investors.
Cadrenal Therapeutics Company Profile
(
Get Free Report)
Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
